Dermatology · Boardman, OH
NPI
1114920204
Since 2005
Specialty
Dermatology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8262 South Ave
Boardman, OH, 44512
Phone (330) 726-8727
Groups this clinician bills Medicare through
Medicare paid, 2024
$146K
3,051 services
Medicare patients, 2024
762
Average age 72
Drug cost, 2024
$6.3M
4,443 prescriptions
Company payments, 2025
$2,008
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James Armile was code 99213 (office e&m - established), 1,268 times for 652 patients. In total James Armile billed 3,051 services in 53 codes, and Medicare paid $146K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,268 | 652 | $51.63 | $65K |
| 17000 Destruction Skin Lesion | Office | 545 | 326 | $35.36 | $19K |
| 17003 Destruction Skin Lesion | Office | 415 | 235 | $4.02 | $1,667 |
| 17110 Destruction Skin Lesion | Office | 211 | 155 | $65.23 | $14K |
| 99203 Office E&M - New | Office | 145 | 145 | $62.79 | $9,104 |
| 11102 Skin Biopsy | Office | 142 | 132 | $55.75 | $7,916 |
| 99214 Office E&M - Established | Office | 31 | 29 | $70.77 | $2,194 |
| 11103 Skin Biopsy | Office | 23 | 19 | $30.17 | $694 |
| 99212 Office E&M - Established | Office | 20 | 18 | $37.39 | $748 |
| 13121 Wound Repair - All Levels | Office | 17 | 14 | $239.02 | $4,063 |
| 13132 Wound Repair - All Levels | Office | 16 | 15 | $316.21 | $5,059 |
| 11104 Skin Biopsy | Office | 15 | 13 | $66.82 | $1,002 |
| 11200 Removal or Shaving of Skin Growth | Office | 14 | 14 | $43.15 | $604 |
| 11604 Skin Lesion Excision | Office | 13 | 11 | $89.30 | $1,161 |
| 11606 Skin Lesion Excision | Office | 11 | 11 | $304.99 | $3,355 |
By year: 2022 $181K for 3,182 services; 2023 $177K for 3,252 services; 2024 $146K for 3,051 services.
Medicare prescription drug claims, 2024
In 2024, the drug James Armile prescribed most often to Medicare patients was Ketoconazole, with 656 prescriptions and refills. In total James Armile wrote 4,443 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 656 | 679 | 265 | $11K |
| Clobetasol Propionate Generic | 453 | 459 | 231 | $16K |
| Triamcinolone Acetonide Generic | 364 | 382 | 237 | $3,006 |
| Ammonium Lactate Generic | 244 | 260 | 99 | $4,504 |
| Doxycycline Hyclate Generic | 175 | 254 | 59 | $4,322 |
| Cephalexin Generic | 171 | 171 | 149 | $1,265 |
| Metronidazole Generic | 145 | 157 | 76 | $8,172 |
| Spironolactone Generic | 133 | 238 | 29 | $1,001 |
| Dupixent Pen Dupilumab | 122 | 124 | 14 | $470K |
| Clindamycin Phosphate Generic | 118 | 128 | 50 | $5,938 |
| Mupirocin Generic | 114 | 114 | 82 | $759 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 113 | 115 | 67 | $891 |
| Dupixent Syringe Dupilumab | 101 | 101 | 11 | $427K |
| Hydroxyzine Hcl Generic | 97 | 123 | 33 | $1,324 |
| Tacrolimus Generic | 81 | 84 | 48 | $9,101 |
Brand drugs: 929 claims; generic drugs: 3,514 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James Armile $2,008 ($2,008 in general payments such as food, travel and fees) from 17 companies. The largest payer was UCB, Inc. with $667.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 43 | $667 |
| Pfizer Inc. PFE | 21 | $217 |
| LEO Pharma Inc. | 9 | $165 |
| Janssen Biotech, Inc. JNJ | 5 | $155 |
| Arcutis Biotherapeutics, Inc. ARQT | 13 | $150 |
| Abbvie Inc. ABBV | 12 | $144 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $112 |
| Incyte Corporation INCY | 4 | $72.64 |
| Lilly USA, LLC LLY | 3 | $69.25 |
| Amgen Inc. AMGN | 4 | $68.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.